Among study participants with gout receiving pegloticase, a total of 1.5% (n=5/328) experienced at least 1 cardiovascular or thromboembolic event. Pegloticase therapy for uncontrolled gout does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results